Featured Videos

John Sterling, GEN‘s Editor-in-Chief, has been attending the Bioprocess International meeting since its inception. In contrast, Julianna LeMieux, PhD, Deputy Editor-in-Chief, attended the meeting for the first time this year. The two sat down with Kevin Davies, PhD,  to talk about the first day of the meeting, the sessions they attended, and the trends that they are noticing.

Boston and Bioprocessing: GEN Reports Live from the First Day at BPI

  In this episode of Close to the Edge from GEN, senior editor Jonathan D. Grinstein, PhD, speaks with Fyodor Urnov, PhD, a pioneer in the field of genome editing. Urnov is a professor of molecular and cell biology at UC Berkeley, the scientific director of technology and translation at the Innovative Genomics Institute in Berkeley, California, and a co-founder of Tune Therapeutics, one of several biotechs exploring epigenome editing. The conversation goes into great detail about Urnov’s background in epigenomics and genome editing, including his time at Sangamo, where his team coined the term “genome editing” in 2005. It then discusses his vision for “CRISPR cures on demand” and the obstacles that currently stand in the way. Urnov also provides insight into the origin story of Tune Therapeutics and how this epigenome editing company stacks up against more recent entrants.

Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning

GEN September 2023 issue cover

It’s September, that time of year when back-to-school feelings come over us whether we’re enrolled in school or not. In keeping with those feelings, GEN is posting a course selection guide, or what we’re normally inclined to call a table of contents. And, yes, there’s a lot of required reading: epigenome editing, nonviral gene therapy delivery systems, liquid biopsies, noncanonical amino acids, and cryogenic electron microscopy. You can take a recess whenever you like, but don’t miss the pep rally, our listing of the top 10 biopharma clusters. It may seem retrospective. But it actually asks us to consider how the interregional competition to accommodate life sciences companies will play out, given current trends in NIH funding, VC funding, patents, laboratory space, and employment. Whichever region you’re in, stay full of that old school spirit. And pick up some extra credit by reading editorials on digital biomanufacturing, bioinformatics challenges, and chemotherapy shortages.